NICE says ‘yes’ to Santen’s dry eye disease treatment, ciclosporin
16 December 2015 | By Victoria White
Ciclosporin (Ikervis) is a sterile, positively charged, oil-in water, unpreserved ophthalmic emulsion that contains ciclosporin (CsA)...
List view / Grid view
News
Versatile Syrris flow reactors feature in a plethora of publications
15 December 2015 | By Versatile Syrris
Today, scientists have access to hundreds of flow chemistry papers citing groundbreaking applications established on modular reactors from Syrris, including the Ley group’s Accelerating Spirocyclic Polyketide Synthesis using Flow Chemistry...
Comic Relief and GSK team up to help fight malaria
15 December 2015 | By Victoria White
A new fund – created through a £17m donation from GSK and £5m from Comic Relief – will provide targeted grants over the next five years to organisations on the malaria frontline...
Pharmaceutical deals crucial to offset R&D costs, says GBI Research
15 December 2015 | By Victoria White
GBI Research’s latest report states that pharmaceutical companies are considering various strategies to overcome the challenge of rising R&D costs, with deal-making the foremost method of boosting short-term revenues...
Allergan’s Viberzi (eluxadoline) now available in the US
15 December 2015 | By Victoria White
Viberzi, a twice daily, oral medication, is Allergan’s first-in-class treatment for irritable bowel syndrome with diarrhoea (IBS-D)...
Amgen reacquires product rights to 3 products from GSK
15 December 2015 | By Victoria White
Amgen has entered into a definitive agreement with GSK to reacquire all of its remaining rights to Prolia (denosumab), XGEVA (denosumab) and Vectibix (panitumumab) in 48 countries...
Sanofi and Boehringer Ingelheim announce business swap
15 December 2015 | By Victoria White
The proposed transaction would consist of an exchange of Sanofi animal health business (Merial) and Boehringer Ingelheim consumer healthcare (CHC) business...
Trial of Ofev and pirfenidone in IPF starts
14 December 2015 | By Victoria White
The trial’s primary endpoint is the percentage of patients with on-treatment gastrointestinal adverse events from baseline to week 12...
FDA approves Vistogard to treat 5-FU or capecitabine overdoses
14 December 2015 | By Victoria White
Vistogard is the first and only antidote for 5-FU and capecitabine overdose and for earlyonset, severe, life-threatening toxicities approved by the FDA...
Nurofen Australia made misleading Specific Pain claims
14 December 2015 | By Victoria White
The Australian Federal Court has found that Reckitt Bensicker (Australia) engaged in misleading conduct in contravention of Australia Consumer Law by representing that its Nurofen Specific Pain Products were each formulated to treat a specific type of pain...
AstraZeneca confirms talks with Acerta Pharma to acquire the company for $5 billion
AstraZeneca today confirmed that it is in talks with Acerta Pharma to acquire the company in a potential deal worth $5 billion.
Cherwell strengthens team with Microbiology Product Specialist appointment
14 December 2015 | By Cherwell Laboratories
Company boosts industrial microbiology expertise to enhance customer support...
Takeda’s Ninlaro capsules now available in the US
14 December 2015 | By Victoria White
Takeda’s Ninlaro (ixazomib) capsules, the first and only oral proteasome inhibitor, are now available in the US for patients with multiple myeloma...
FDA approves Roche’s Alecensa for ALK-positive NSCLC
14 December 2015 | By Victoria White
Alecensa (alectinib) is approved for patients whose disease has worsened after, or who could not tolerate treatment with Xalkori (crizotinib)...
BMS and Pfizer announce new data for Eliquis (apixaban)
11 December 2015 | By Victoria White
In the data from the Phase 3 AMPLIFY study, Eliquis (apixaban) was comparable to conventional therapy in recurrent venous thromboembolism (VTE)...
